30 The newest class of medications, the sodium-glucose cotransporter 2 inhibitors canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance), increase urinary glucose excretion by interfering with the reabsorption of glucose in the proximal renal tubule
To the possible persistence of the initial pathogen that triggered the PAIS, one should add the reactivation of latent viruses such as EBV, HHV-6 or VZV (8285), all frequently observed in PAIS, possibly as a result of a reduced efficiency of their control by the immune system
Moreover, several large-scale clinical trials 6,7,8,9,10 such as LEADER, SUSTAIN-6, and REWIND have demonstrated that GLP-1RAs can reduce the incidence of MACEs in patients with T2D and established cardiovascular disease or high cardiovascular risk
& Chwatko, G